Previous 10 | Next 10 |
STAMFORD, Conn., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, recently published two studies demonstrating the utility of machine learning to predict clinical outcomes for postpartum hemorrhage (PPH). The s...
STAMFORD, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate at the following virtual investor conferences: Stifel 2021 Virtual Healthcare Confe...
STAMFORD, Conn., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the third quarter of 2021 after the market close on Monday, November 15, 2021. On the same...
STAMFORD, Conn., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sema4 , an AI-driven genomic and clinical data intelligence platform company, today announced the appointment of Gustavo Stolovitzky , PhD, to the newly established senior leadership position of Chief Science Officer (CSO). Dr....
STAMFORD, Conn., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Sema4 , an AI-driven genomic and clinical data intelligence platform company, today announced the launch of Sema4 Elements™ , a portfolio of information-driven genomic solutions, digital tools for patients and providers, and...
STAMFORD, Conn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt , Ph.D., Founder and Chief Executive Officer, and Isaac Ro , Chief Financial Officer will participate at th...
Home Depot (NYSE:HD) issued the spotlight earnings report on Tuesday, sending ripples across the market. This included the homebuilding sector, which was one of the biggest drags on the day amid weak comparable sales at the country's biggest home improvement retailer. The sector also lost gro...
Shares of Sema4 Holdings (NASDAQ: SMFR) were sinking 17.7% as of 11:36 a.m. EDT on Tuesday. The decline came after the genomic and clinical data intelligence platform company announced its second-quarter results following the market close on Monday. Sema4 reported Q2 revenue of ...
85% test-volume growth (excluding COVID-19 tests) compared to same period in 2020 Recorded 56% growth in total revenue of $46.9 million Expanded health system partnerships to include NorthShore University, AdventHealth, and Avera Health Commitment to 2023 target ...
SIOUX FALLS, S.D and STAMFORD, Conn., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Avera Health , an integrated regional health care system that serves 300 locations across the Upper Midwest, and Sema4 , a patient-centered health intelligence company, today announced a new collaboration launch...
News, Short Squeeze, Breakout and More Instantly...
Sema4 Holdings Corp. Company Name:
SMFR Stock Symbol:
NASDAQ Market:
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...